• 1
    Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41(4 Suppl 3): IIV, S1–S91.
  • 2
    Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158165.
  • 3
    Ducloux D, Kazory A, Chalopin J-M. Predicting coronary heart disease in renal transplant recipients: A prospective study. Kidney Int 2004; 66: 441447.
  • 4
    Groth CG, Backman L, Morales JM et al. for Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 10361042.
  • 5
    Kahan BD. for Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. Lancet 2000; 356: 194202.
  • 6
    Kreis H, Cisterne J-M, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 12521260.
  • 7
    Blum CB. Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model. Am J Transplant 2002; 2: 551559.
  • 8
    Tedesco Silva H Jr., Felipe CR, Machado PGP et al. Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. Transplant Proc 2003; 35(Suppl 3 A): 177S180S.
  • 9
    Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 10701076.
  • 10
    Martinez-Mier G, Mendez-Lopez MT, Budar-Fernandez LF et al. Living related kidney transplantation without calcineurin inhibitors: Initial experience in a Mexican center. Transplantation 2006; 82: 15331536.
  • 11
    Büchler M, Caillard S, Barbier S et al. Sirolimus versus cyclosporine in kidney recipients receiving Thymoglobulin®, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 25222531.
  • 12
    Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S. for Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months. Transplantation 2003; 75: 12131220.
  • 13
    Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77: 252258.
  • 14
    van Hooff JP, Squifflet J-P, Wlodarczyk Z, Vanrenterghem Y, Paczek L. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 2003; 75: 19341939.
  • 15
    Vitko S, Wlodarczyk Z, Kyllonen L et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study. Am J Transplant 2006; 6: 531538.
  • 16
    Vitko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 25212530.
  • 17
    Lorber MI, Mulgaonkar S, Butt KMH et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244252.
  • 18
    Vitko S, Margreiter R, Weimar W et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 15321540.
  • 19
    Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514522.
  • 20
    Flechner SM, Goldfarb D, Solez K et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883892.
  • 21
    Hoogeveen RC, Ballantyne CM, Pownall HJ et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 2001; 72: 12441250.
  • 22
    Morrisett JD, Abdel-Fattah G, Hoogeveen R et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 11701180.
  • 23
    Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Sirolimus modifies cholesterol homeostasis in hepatic cells: A potential molecular mechanism for sirolimus-associated dyslipidemia. Transplantation 2007; 84: 10291036.
  • 24
    Massy ZA, De Bandt JP, Morelon E, Thevenin M, Lacour B, Kreis H. Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A. Nephrol Dial Transplant 2000; 15: 928.
  • 25
    Um SH, Frigerio F, Watanabe M et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431: 200205.
  • 26
    Maluf DG, Mas VR, Archer KJ et al. Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment. Transplantation 2005; 80:17051711.
  • 27
    Elloso MM, Azrolan N, Sehgal SN et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3: 562569.
  • 28
    Varghese Z, Fernando R, Moorhead JF, Powis SH, Ruan XZ. Effects of sirolimus on mesangial cell cholesterol homeostasis: A novel mechanism for its action against lipid-mediated injury in renal allografts. Am J Physiol Renal Physiol 2005; 289: F43-F48.
  • 29
    Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, Andres V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis 2004; 172: 3138.
  • 30
    Yang K, Li D, Luo M, Hu Y. Generation of HSP60-specific regulatory T cell and effect on atherosclerosis. Cell Immunol 2006; 243: 9095.
  • 31
    Ma KL, Ruan XZ, Powis SH, Moorhead JF, Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2007; 292: H2721-H2728.
  • 32
    Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998; 279: 16151622.
  • 33
    Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313321.
  • 34
    Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 11491158.
  • 35
    Kasiske B, Cosio FG, Beto J et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4(Suppl 7): 1353.
  • 36
    Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 20242031.
  • 37
    National Institutes of Health, National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive Summary. May 2001. Report No. 013670.
  • 38
    Nogueira J, Weir M. The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. Clin J Am Soc Nephrol 2007; 2: 766785.
  • 39
    Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 722.
  • 40
    Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 12671278.
  • 41
    Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006; 6: 770774.
  • 42
    Puthenparumpil JJ, Keough-Ryan T, Kiberd M, Lawen J, Kiberd BA. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 2005; 37: 10331035.
  • 43
    Wali RK, Mohanlal V, Ramos E et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007; 7: 15721583.